Skip to main content
. 2023 Feb 22;13:1040665. doi: 10.3389/fonc.2023.1040665

Figure 7.

Figure 7

Response of HBCx39 PDX and PDXC to paclitaxel, capecitabine and everolimus. (A) Relative tumor volume (normalized to the volume at the day when the treatment was started) of non-treated and treated HBCx39 PDX; the treatment was as follows: paclitaxel (15 mg/kg, 2x/week), capecitabine (755 mg/kg, 5x/week) and everolimus (5 mg/kg, 5x/week). (B) Relative total fragment area normalized to the area at the start of the treatment; average ± StDv (3-4 parallels for each condition in one representative experiment). (C) The total fragment area in the treated cultures (day 19) shown as a percentage of the untreated controls; average ± SEM (n=3 for paclitaxel and capecitabine) and ± StDv (n=2 for everolimus); * and **, p < 0.05 by unpaired and paired t-test, respectively. (D) Representative fluorescence pictures of PDXCs treated with/without the indicated drugs for 19 days before staining with calcein and PI; scale bar, 200 μm.